Albaconazole

Drug Profile

Albaconazole

Alternative Names: UR-9825; W 0027

Latest Information Update: 30 Jul 2015

Price : $50

At a glance

  • Originator Uriach
  • Developer Stiefel Laboratories
  • Class Antifungals; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Tinea pedis
  • Discontinued Chagas disease; Mycoses; Onychomycosis; Vulvovaginal candidiasis

Most Recent Events

  • 06 Aug 2013 Albaconazole licensed to Actavis worldwide
  • 08 Jan 2010 Albaconazole is still in active development
  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top